B
Bull
Bull · 25%VXRT
$1.66
Precio del escenario
$0.320
-0.080 (-25.06%)Al cierre
Loading chart…
- High
- 0.430
- Open
- 0.412
- VWAP
- 0.35
- Vol
- 24.02M
- Mkt Cap
- 118.17M
- Low
- 0.300
- Amount
- 8.41M
- EV/EBITDA, TTM
- -7.36
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Métricas de valoración
The current forward P/E ratio for Vaxart Inc (VXRT) is -1.49, compared to its 5-year average forward P/E of -3.00.
Alphio AI Price Scenarios for VXRT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.007-17NewsfilterVaxart Annual Meeting Results Show Key Approvals
8.506-26NewsfilterVaxart Board's Strategic Actions to Drive Value Creation
- 9.505-09seekingalpha
Vaxart Reports Q1 2026 Earnings with Strategic Updates
- 9.505-01Newsfilter
Vaxart to Report Q1 2026 Financial Results on May 7
- 5.004-23Newsfilter
Vaxart Appoints New Board Member to Enhance Vaccine Development Expertise
VXRT FAQ — answered by Alphio AI
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.